From bases to breakthroughs: Editing cancer’s weak spots with CRISPR

2026-05-26T13:53:09+01:0026 May 2026|

In the latest installment of our innovator blog series, we caught up with Dr Matthew Coelho, Cancer Research UK Career Development Fellow at the Wellcome Sanger Institute. Matthew works within the Somatic Genomics programme and is co-founder of BASE Rx alongside Group Leader, Dr Mathew Garnett.

Bugs as drugs – Innovating in the Microbiome space

2025-05-06T12:41:28+01:006 May 2025|

We spoke to Dr Trevor Lawley, Senior Group Leader at the Wellcome Sanger Institute who works in the Parasites and Microbes Programme.  Trevor’s is the story of turning basic, fundamental research into innovative science with potential to treat a broad range of human diseases.

Tackling trypanosomiasis in cattle in sub-Saharan Africa

2024-07-05T10:40:12+01:006 February 2024|

Three vaccine targets discovered by the Wellcome Sanger Institute focus on targeting animal trypanosomiasis in an effort to find a cure for a disease that causes billions in economic losses in one of the poorest regions on earth. These losses fall heavily on small holders, who are often heavily dependent on livestock for their livelihood.

Trailblazing Genomics

2023-10-11T15:12:57+01:0011 October 2023|

As a top UK innovator, the Sanger Institute’s work is foundational to many. We enable partners to apply our science and advance it to develop products, services and therapeutics - solving real-world problems

Mosaic’s becoming

2024-07-05T10:46:37+01:0012 September 2023|

The Sanger Institute is committed to innovative science at scale, but we need partners and investors to transfer this science into the clinic. Mariya Chhatriwala, Business Development Manager, gives us her insights on how the Sanger Institute’s fifth spin-out company came to be.